Pamidronate Disodium Tillomed Laboratories Limited

Pamidronate disodium, the active ingredient in Pamidronate Disodium Tillomed Laboratories Limited, is a bisphosphonate presented as a sterile injectable solution for intravenous use. It is used to manage bone resorption disorders in adult patients, including those with cancer‑related bone disease. GNH USA supplies Pamidronate Disodium Tillomed Laboratories Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

GNH USA supplies Pamidronate Disodium Tillomed Laboratories Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Pamidronate disodium is indicated for conditions that involve increased osteoclastic activity and abnormal bone turnover.

- Hypercalcaemia of malignancy: reduces serum calcium levels and alleviates related symptoms. - Bone metastases from solid tumours: helps to reduce skeletal‑related events such as pathological fractures. - Paget’s disease of bone: normalises bone remodeling and decreases bone pain. - Osteogenesis imperfecta (severe forms): improves bone density and reduces fracture risk. - Primary hyperparathyroidism: assists  as an adjunct  to surgery  or when surgery  is  not  feasible. - Chronic  renal  osteodystrophy  in  dialysis  patients  with  high  bone  turnover  (  if  approved  by  the  regulatory  authority).

Common           …   …  …  …  …  …  …  …   t  …   t  

Intro